Immune system differences in men with hypo- or hypercholesterolemia

Clinical Immunology and Immunopathology

Volumn 84, Issue 2, 1997, Pages 145-149

  Muldoon, Matthew F ^a   Marsland, Anna ^a   Flory, Janine D ^a   Rabin, Bruce S ^b   Whiteside, Theresa L ^b,c   Manuck, Stephen B ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIA; IMMUNE SYSTEM; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0031214145     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4382     Document Type: Article

References (37)

1. Kritchevsky S. B. Serum cholesterol and cancer risk: An epidemiologic perspective. Annu. Rev. Nutr. 12:1992;391-416.
2. Jacobs D., Blackburn H., Higgins M., Reed D., Iso H., McMillian G., Neaton J., Nelson J., Potter J., Rifkind B., Rossouw J., Shekelle R., Yusuf R. Report of the conference on low blood cholesterol: Mortality associations. Circulation. 86:1992;1046-1060.
3. Neaton J. D., Blackburn H., Jacobs D., Kuller L., Lee D. J., Sherwin R., Chir B., Shih J., Stamler J., Wentworth D. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Arch. Intern. Med. 152:1992;1490-1500.
4. Marenah C. B., Lewis B., Hassall D., La Ville A., Cortese C., Mitchell W. D., Bruckdorfer K. R., Slavin B., Miller N. E., Turner P. R., Heduan E. Hypocholesterolaemia and noncardiovascular disease: Metabolic studies on subjects with low plasma cholesterol concentrations. Br. Med. J. 286:1983;1603-1606.
5. Losche W., Krause S., Pohl A., Pohl C., Liebrenz A., Schauer I., Ruhling K., Till U. Functional behaviour of monuclear blood cells from patients with hypercholesterolemia. Thrombosis Res. 65:1992;337-342.
6. Paffenbarger R. S., Wing A. L., Hyde R. T. Physical activity as an index of heart attack risk in college alumni. Am. J. Epidemiol. 108:1978;161-175.
7. Muldoon M. F., Herbert T. B., Patterson S. M., Kameneva M., Raible R., Manuck S. B. Effects of acute phychological stress on serum lipids, hemoconcentration, and blood viscosity. Arch. Int. Med. 155:1995;615-620.
8. Herbert T. B., Coriell M., Cohen S. Analysis of lymphocyte proliferation data: Do different approaches yield the same result? Brain Rehav. Immun. 8:1994;153-162.
9. Whiteside T. L., Herberman R. B. Measurements of natural killer cell members and function in humans. Neuroimmunology," Vol. 24, "Methods in Neuroscience. 1994;Academic Press, Orlando. p. 10-23.
10. Lipid Research Clinical Population Studies Data Book. 1980;U.S. Department of Health and Human Resources.
11. Muldoon M. F., Kritchevsky S. B., Evans R. W., Kagan V. E. Serum total antioxidant activity in relative hypo- and hypercholesterolemia. Free Radicals Res. 25:1996;239-245.
12. Sullivan D. Cholesterol and noncardiovascular disease: Basic science. Austr. N. Z. J. Med. 24:1994;92-97.
13. Kelley D. S., Bendich A. Essential nutrients and immunologic functions. Amer. J. Clin. Nutr. 63:1996;994S-996S.
14. Heiniger H. J., Brunner K. T., Cerottini J. C. Cholesterol is a critical cellular component for T-lymphocyte cytotoxicity. Proc. Natl. Acad. Sci. USA. 75:1978;5683-5687.
15. Pace D. M., Esfahani M. The effects of cholesterol depletion on cellular morphology. Anat. Rec. 219:1987;135-143.
16. Bendich A. Antioxidant micronutrients and immune responses. Ann. N.Y. Acad. Sci. 587:1990;168-180.
17. Owens D., Collins P., Johnson A., Tomkin G. Cellular cholesterol metabolism in mitogen-stimulated lymphocytes - Requirement for de novo synthesis. Biochim. Biophys. Acta. 1051:1990;138-143.
18. Hughes D. A., Townsend P. J., Haslam P. L. Enhancement of the antigen-presenting function of monocytes by cholesterol: Possible relevance to inflammatory mechanisms in extrinsic allergic alveolitis and atherosclerosis. Clin. Exp. Immunol. 87:1992;279-286.
19. Kreuzer J., Bader J., Jahn L., Hautman M., Kubler W., Von Hodenberg E. Chemotasix of the monocyter cell line U937: Dependence on cholesterol and early mevalonate pathway products. Atherosclerosis. 90:1991;203-209.
20. Flegel W. A., Wolpl A., Mannel D. N., Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect. Immunity. 57:1989;2237-2245.
21. Shor-Posner G., Basit A., Ying L., Cabrejos C., Chang J., Fletcher M., Mantero-Atienza E., Baum M. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Amer. J. Med. 94:1993;515-519.
22. Harmony J. A. K., Akeson A. L., McCarthy B. M., Morris R. E., Scupham D. W., Grupp S. A. Scanu A. M., Spector A. A. Biochemistry and Biology of Plasma Lipoproteins. 1986;403-452 Dekker, New York.
23. Kos W. L., Loria R. M., Snodgrass M. J., Cohen D., Thorpe T. G., Kaplan A. M. Inhibition of host resistance by nutritional hypercholesteremia. Infect. Immunity. 26:1979;658-667.
24. Schectman G., Kaul S., Mueller R. A., Borden E. C., Kissebah A. H. The effects of interferon on the metabolism of LDLs. Arterioscler. Thromb. 12:1992;1053-1062.
25. Ettinger W. H., Miller L. A., Smith T. K., Parks J. S. Effect of interleukin-1 alpha on lipoprotein lipids in cynomolgus monkeys: Comparison to tumor necrosis factor. Biochim. Biophys. Acta. 1128:1992;186-192.
26. Cutts J. L., Bankhurst A. D. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme a reductase by lovastatin. Int. J. Immunopharmacol. 11:1989;863-869.
27. Cutts J. L., Scallen T. J., Watson J., Bankhurst A. D. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J. Cell Physiol. 139:1989;550-557.
28. Law R. E., Stimmel J. B., Damore M. A., Carter C., Clarke S., Wall R. Lipopolysaccharide-induced NF-κB activation in mouse 70Z/3 pre-B lymphocytes is inhibited by mevinolin and 5′-methylthioadenosine: Roles of protein isoprenylation and carboxyl methylation reactions. Mol. Cell. Biol. 12:1992;103-111.
29. Kazanecki M. E., Melhem M. F., Spichty K. J., Kelly R. H., Rao K. N. Diet-induced reduction in serum lipoproteins stimulates cell proliferation in weanling rats. Pharmacol. Res. 21:1989;533-547.
30. Melhem M. F., Gabriel H. F., Eskander E. D., Rao K. N. Cholestyramine promotes 7,12-dimethylbenzanthracene induced mammary cancer in Wistar rats. Br. J. Cancer. 6:1987;45-48.
31. Newman T. B., Hulley S. B. Carcinogenicity of lipid-lowering drugs. J. Am. Med. Assoc. 275:1996;55-60.
32. Kobashigawa J. A., Katznelson S., Laks H., Johnson J. A., Yeatman L., Want X. M., Chia D., Terasaki P. I., Sabad A., Cogert G. A., Trosian K., Hamilton M. A., Moriguchi J. D., Kawata N., Hage A., Drinkwater D. C., Stevenson L. W. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333:1995;621-627.
33. Dayton S., Pearce M. L., Hashimoto S., Dixon W. J., Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat inpreventing complications of atherosclerosis. Circulation. 40:1969;1-63.
34. Br. Heart J. 40:1978;1069-1118.
35. Muldoon M. F., Manuck S. B., Matthews K. A. Effects of cholesterol lowering on mortality: A quantitative review of primary prevention trials. Br. Med. J. 301:1990.
36. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1995;1301-1307.
37. Lancet. 344:1994;1383-1389.